Ampulle <Technik>

Impfstoff Pfizer-BioNTech COVID-19 Vaccine

to related objects

Impffläschchen, sog. Vials, aus Transparentglas ("Neutralglas") mit bedrucktem Etikett, aufgeschweißter Metalldeckel mit rundem Gummi-Inlay für den Injektionsnadeleinstich.

Der Impfstoff von BioNTech / Pfizer erhielt am 21.Dezember 2020 um 18.30 Uhr von der Europäischen Kommission seine Notfallzulassung. Vorausgegangen war eine Impfstoffentwicklung im Rekordtempo, die das deutsche Unternehmen aus Mainz mit Hilfe des US-Pharmakonzerns Pfizer markt- und zulassungsreif ausentwickelte.

Hersteller der Glasfläschchen, die für den globalen Markt in Deutschland produziert werden, ist die Firma Schott AG, die sie in MItterteich / Oberpfalz produziert.

Wie kaum ein anderer Gegenstand aus der Zeit der Corona-Pandemie standen diese Phiolen für die Hoffnung und Erwartung auf eine Überwindung der Krise.

Location
Badisches Landesmuseum, Karlsruhe
Collection
Glas
Inventory number
2021/1-10
Measurements
Höhe: 3.0 cm, Durchmesser: 1.5 cm, Volumen: 0.3 cm
Material/Technique
Glas; Metall; Fertigung

Event
Herstellung
(who)
BioNTech SE
Pfizer Inc.
Schott AG Mainz
(where)
Mainz
New York, NY
Mitterteich
(when)
2020

Rights
Badisches Landesmuseum
Last update
12.07.2024, 10:56 AM CEST

Data provider

This object is provided by:
Badisches Landesmuseum Karlsruhe. If you have any questions about the object, please contact the data provider.
Show original at data provider

Object type

  • Ampulle <Technik>

Associated

  • BioNTech SE
  • Pfizer Inc.
  • Schott AG Mainz

Time of origin

  • 2020

Other Objects (12)

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Vertrieb und Herstellung von Impfstoffen: Firma Pfizer

Archivale

Vertrieb und Herstellung von Impfstoffen: Firma Pfizer

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA

Evidence of abnormal trading on COVID-19 Pfizer vaccine development information

Artikel

Evidence of abnormal trading on COVID-19 Pfizer vaccine development information

Reactivation of minimal change disease after Pfizer vaccine against COVID-19

Reactivation of minimal change disease after Pfizer vaccine against COVID-19

Herpetic anterior uveitis following Pfizer–BioNTech coronavirus disease 2019 vaccine: two case reports

Herpetic anterior uveitis following Pfizer–BioNTech coronavirus disease 2019 vaccine: two case reports

Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases

Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases

Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France

Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France

Metabolic syndrome and the immunogenicity of Pfizer–BioNTech vaccine: a cross-sectional study in Japanese healthcare workers

Metabolic syndrome and the immunogenicity of Pfizer–BioNTech vaccine: a cross-sectional study in Japanese healthcare workers

A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia

A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia

Related objects